Neuberger Berman Group LLC Has $2.08 Million Position in GSK PLC Sponsored ADR (NYSE:GSK)

Key Points

• Neuberger Berman Group LLC increased its holdings in GSK PLC by 59.2% in Q1, acquiring an additional 19,923 shares, bringing its total ownership to 53,599 shares valued at approximately $2.08 million.
• Analysts have mixed views on GSK, with one firm downgrading it to a "strong sell" while another upgraded it to a "buy"; currently, the stock has an average rating of "Hold" with a consensus price target of $37.38.
• GSK announced a quarterly dividend of $0.4206 per share, representing an annualized payout of $1.68 and a yield of 4.3%, with a dividend payout ratio of 79.17%.

Neuberger Berman Group LLC increased its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 59.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,599 shares of the pharmaceutical company's stock after buying an additional 19,923 shares during the quarter. Neuberger Berman Group LLC's holdings in GSK were worth $2,076,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in GSK. HHM Wealth Advisors LLC grew its stake in shares of GSK by 222.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after buying an additional 460 shares during the period. Costello Asset Management INC acquired a new stake in shares of GSK in the 1st quarter valued at $31,000. Richardson Financial Services Inc. raised its stake in GSK by 127.9% during the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares in the last quarter. Olde Wealth Management LLC acquired a new stake in GSK during the 1st quarter worth $36,000. Finally, Cary Street Partners Investment Advisory LLC grew its position in GSK by 525.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after purchasing an additional 852 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Performance

GSK traded up $0.07 during trading on Friday, reaching $39.30. 3,038,539 shares of the company's stock were exchanged, compared to its average volume of 4,586,450. The company has a market capitalization of $80.08 billion, a P/E ratio of 18.19, a PEG ratio of 1.71 and a beta of 0.51. The business has a 50 day moving average price of $38.50 and a 200 day moving average price of $37.99. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $44.67. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%. The firm's revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.43 earnings per share. As a group, analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be given a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.3%. GSK's payout ratio is currently 77.78%.

Wall Street Analysts Forecast Growth

GSK has been the subject of several research reports. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Finally, Berenberg Bank reiterated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, GSK currently has an average rating of "Hold" and an average target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.